CoChat
Sign Up
Cited by 310

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, Cui-Cui, Wang, Zhen-Ling, Xu, Ting, He, Zhi-Yao, Wei, Yu-Quan·2020·Biotechnology Advances
DOI 10.1016/j.biotechadv.2019.107502
Open this paper in CoChat — free account

Abstract

With the improvement of gene vectors, the rise of chimeric antigen receptor T cell immunotherapy and breakthroughs in the genome editing technology, gene therapy had once again returned to the central stage of disease treatment. It had brought new choices to clinical therapy of diseases such as tumors and genetic diseases, and had changed the status quo of treatment for monogenic disorders and diffuse large B-cell lymphoma. Until August 2019, 22 gene medicines had been approved by the drug regulatory agencies from various countries, but there were few relevant reviews of combing these drugs systematically. Consequently, this review summarizes the gene therapy drugs approved worldwide from 1998 to 2019 in details, including names, indications, dates of approval, companies, vectors, the applied technologies and mechanisms of gene therapy drugs, etc. Furthermore, the gene therapy drugs were classified and addressed in accordance with the employed vectors. Gene therapy had gradually been accepted by the government and the public since 1980s, and have become a new and important alternative to existing treatments for human diseases in the past few years. Therefore, gene therapy drugs, with safe vectors and advanced biotechnologies, would play a greater role in the prevention and treatment of human diseases in future.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biotechadv.2019.107502

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 156

  1. Aartsma-Rus, 2019, A sequel to the Eteplirsen Saga: Eteplirsen is approved in the United States but was not approved in Europe, Nucleic Acid Ther., 29, 13, 10.1089/nat.2018.0756 · DOI
  2. Adam, 2016, NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma, Lancet Oncol., 17, 1485, 10.1016/S1470-2045(16)30489-2 · DOI
  3. Adams, 2017, Targeting noncoding RNAs in disease, J. Clin. Invest., 127, 761, 10.1172/JCI84424 · DOI
  4. Ameri, 2018, Prospect of retinal gene therapy following commercialization of Voretigene Neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation, J. Curr. Ophthalmol., 30, 1, 10.1016/j.joco.2018.01.006 · DOI
  5. Andtbacka, 2015, Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma, J. Clin. Oncol., 33, 2780, 10.1200/JCO.2014.58.3377 · DOI
  6. Andtbacka, 2019, Biodistribution, shedding, and transmissibility of the oncolytic virus Talimogene Laherparepvec in patients with melanoma, EBioMedicine, 47, 89, 10.1016/j.ebiom.2019.07.066 · DOI
  7. Athanasopoulos, 2017, Nonintegrating gene therapy vectors, Hematol. Oncol. Clin. North Am., 31, 753, 10.1016/j.hoc.2017.06.007 · DOI
  8. Bach, 2017, FDA approval of Tisagenlecleucel: promise and complexities of a $475000 cancer drug, JAMA, 318, 1861, 10.1001/jama.2017.15218 · DOI
  9. Barc, 2019, Treatment of critical limb ischemia by pIRES/VEGF165/HGF administration, Ann. Vasc. Surg., 60, 346, 10.1016/j.avsg.2019.03.013 · DOI
  10. Bauer, 2017, The path to successful commercialization of cell and gene therapies: empowering patient advocates, Cytotherapy, 19, 293, 10.1016/j.jcyt.2016.10.017 · DOI
  11. Benson, 2018, Inotersen treatment for patients with hereditary Transthyretin Amyloidosis, N. Engl. J. Med., 379, 22, 10.1056/NEJMoa1716793 · DOI
  12. Benson, 2019, Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis, Neurodegener. Dis. Manag., 9, 25, 10.2217/nmt-2018-0037 · DOI
  13. Bernstein, 2001, Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature, 409, 363, 10.1038/35053110 · DOI
  14. Bonini, 1997, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276, 1719, 10.1126/science.276.5319.1719 · DOI
  15. Bonini, 2003, Safety of retroviral gene marking with a truncated NGF receptor, Nat. Med., 9, 367, 10.1038/nm0403-367 · DOI
  16. Bouchkouj, 2019, FDA approval summary: Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma, Clin. Cancer Res., 25, 1702, 10.1158/1078-0432.CCR-18-2743 · DOI
  17. Chakradhar, 2018, Treatments that made headlines in 2018, Nat. Med., 24, 1785, 10.1038/s41591-018-0292-3 · DOI
  18. Chavez-Pena, 2018, RNA interference technology to improve the baculovirus-insect cell expression system, Biotechnol. Adv., 36, 443, 10.1016/j.biotechadv.2018.01.008 · DOI
  19. Chawla, 2019, A phase I-II study using Rexin-G tumor-targeted retrovector encoding a dominant-negative Cyclin G1 inhibitor for advanced pancreatic cancer, Mol. Ther. Oncolytics, 12, 56, 10.1016/j.omto.2018.12.005 · DOI
  20. Chen, 2018, Nucleic acid-based therapeutics for pulmonary diseases, AAPS PharmSciTech, 19, 3670, 10.1208/s12249-018-1183-0 · DOI
  21. Chi, 2017, Safety of antisense oligonucleotide and siRNA-based therapeutics, Drug Discov. Today, 22, 823, 10.1016/j.drudis.2017.01.013 · DOI
  22. Chira, 2018, Restoring the p53 'guardian' phenotype in p53-deficient tumor cells with CRISPR/Cas9, Trends Biotechnol., 36, 653, 10.1016/j.tibtech.2018.01.014 · DOI · Paper page
  23. Chow, 2018, Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma, Blood, 132, 777, 10.1182/blood-2018-04-839217 · DOI
  24. Ciceri, 2016, Blood, 182, 4599, 10.1182/blood.V128.22.4599.4599 · DOI
  25. Coelho, 2013, Safety and efficacy of RNAi therapy for transthyretin amyloidosis, N. Engl. J. Med., 369, 819, 10.1056/NEJMoa1208760 · DOI · Paper page
  26. Conry, 2018, Talimogene Laherparepvec: first in class oncolytic virotherapy, Hum. Vaccin. Immunother., 14, 839, 10.1080/21645515.2017.1412896 · DOI · Paper page
  27. Cox, 2015, Therapeutic genome editing: prospects and challenges, Nat. Med., 21, 121, 10.1038/nm.3793 · DOI · Paper page
  28. Dabbous, 2019, Survival, motor function, and motor milestones: comparison of AVXS-101 relative to Nusinersen for the treatment of infants with Spinal Muscular Atrophy type 1, Adv. Ther., 36, 1164, 10.1007/s12325-019-00923-8 · DOI
  29. Danisovic, 2018, Induced pluripotent stem cells for Duchenne Muscular Dystrophy modeling and therapy, Cells, 7, E253, 10.3390/cells7120253 · DOI
  30. Deev, 2015, pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia, J. Cardiovasc. Pharmacol. Ther., 20, 473, 10.1177/1074248415574336 · DOI
  31. Deev, 2017, Results of an international postmarketing surveillance study of pl-VEGF165 safety and efficacy in 210 patients with Peripheral Arterial Disease, Am. J. Cardiovasc. Drugs, 17, 235, 10.1007/s40256-016-0210-3 · DOI
  32. Deev, 2018, Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication, Ther. Adv. Cardiovasc. Dis., 12, 237, 10.1177/1753944718786926 · DOI
  33. Dias, 2018, Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives, Prog. Retin. Eye Res., 63, 107, 10.1016/j.preteyeres.2017.10.004 · DOI
  34. Dolgin, 2017, Epic $12 billion deal and FDA’s approval raise CAR-T to new heights, Nat. Biotechnol., 35, 891, 10.1038/nbt1017-891 · DOI
  35. Donde, 2017, Challenges and advances in gene therapy approaches for neurodegenerative disorders, Curr. Gene Ther., 17, 187, 10.2174/1566523217666171013124150 · DOI
  36. Edelstein, 2004, Gene therapy clinical trials worldwide 1989-2004-an overview, J. Gene Med., 6, 597, 10.1002/jgm.619 · DOI
  37. Edelstein, 2007, Gene therapy clinical trials worldwide to 2007--an update, J. Gene Med., 9, 833, 10.1002/jgm.1100 · DOI
  38. Evans, 2018, Arthritis gene therapy approved in Korea, J. Am. Acad. Orthop. Surg., 26, e36, 10.5435/JAAOS-D-17-00695 · DOI
  39. Evans, 2018, Arthritis gene therapy is becoming a reality, Nat. Rev. Rheumatol., 14, 381, 10.1038/s41584-018-0009-5 · DOI
  40. Farkas, 2017, Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe, Front. Med. (Lausanne), 4, 53, 10.3389/fmed.2017.00053 · DOI
  41. Feins, 2019, An introduction to Chimeric Antigen Receptor (CAR) T cell immunotherapy for human cancer, Am. J. Hematol., 94, S3, 10.1002/ajh.25418 · DOI · Paper page
  42. Fellmann, 2014, Stable RNA interference rules for silencing, Nat. Cell Biol., 16, 10, 10.1038/ncb2895 · DOI
  43. Fitzgerald, 2014, Dicer-related helicase 3 forms an obligate dimer for recognizing 22G-RNA, Nucleic Acids Res., 42, 3919, 10.1093/nar/gkt1383 · DOI
  44. Forster, 2018, Gene therapy for peripheral arterial disease, Cochrane Database Syst. Rev., 10
  45. Friedmann, 2004, Clinical gene therapy: lessons from the ether dome, Mol. Ther., 10, 205, 10.1016/j.ymthe.2004.07.009 · DOI
  46. Friedmann, 1972, Gene therapy for human genetic disease?, Science, 175, 949, 10.1126/science.175.4025.949 · DOI
  47. Gage, 1998, Cell therapy, Nature, 392, 18
  48. Ginn, 2013, Gene therapy clinical trials worldwide to 2012 - an update, J. Gene Med., 15, 65, 10.1002/jgm.2698 · DOI
  49. Glascock, 2017, Cure SMA and our patient community celebrate the first approved drug for SMA, Gene Ther., 24, 498, 10.1038/gt.2017.39 · DOI
  50. Goins, 2016, Retargeting of herpes simplex virus (HSV) vectors, Curr. Opin. Virol., 21, 93, 10.1016/j.coviro.2016.08.007 · DOI
  51. Golchin, 2019, Biological products: cellular therapy and FDA approved products, Stem Cell Rev. Rep., 15, 166, 10.1007/s12015-018-9866-1 · DOI
  52. Gordon, 2009, The 'timely' development of Rexin-G: first targeted injectable gene vector (review), Int. J. Oncol., 35, 229
  53. Gordon, 2010, Rexin-G, a targeted genetic medicine for cancer, Expert. Opin. Biol. Ther., 10, 819, 10.1517/14712598.2010.481666 · DOI
  54. Gordon, 2018, Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. Mol, Clin. Oncol., 9, 115
  55. Gorenoi, 2017, Growth factors for angiogenesis in peripheral arterial disease, Cochrane Database Syst. Rev., 6
  56. Goswami, 2019, Gene therapy leaves a vicious cycle, Front. Oncol., 9, 297, 10.3389/fonc.2019.00297 · DOI
  57. Goyal, 2018, Making sense of antisense oligonucleotides: A narrative review, Muscle Nerve, 57, 356, 10.1002/mus.26001 · DOI
  58. Greco, 2015, Improving the safety of cell therapy with the TK-suicide gene, Front. Pharmacol., 6, 95, 10.3389/fphar.2015.00095 · DOI
  59. Gruntman, 2018, The rapidly evolving state of gene therapy, FASEB J., 32, 1733, 10.1096/fj.201700982R · DOI
  60. Guo, 2018, Development of gene therapeutics for head and neck cancer in China: from bench to bedside, Hum. Gene Ther., 29, 180, 10.1089/hum.2017.230 · DOI
  61. Ha, 2012, Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients, Cytotherapy, 14, 247, 10.3109/14653249.2011.629645 · DOI
  62. Hanna, 2017, Gene therapies development: Slow progress and promising prospect, J. Mark. Access Health Policy, 5
  63. Harrison, 2019, Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods, Cytotherapy, 21, 224, 10.1016/j.jcyt.2019.01.003 · DOI
  64. Hassan, 2012, Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency, Blood, 120, 3615, 10.1182/blood-2011-12-396879 · DOI
  65. Hayne, 2017, Biochemical analysis of the lipoprotein lipase truncation variant, LPL(S447X), reveals increased lipoprotein uptake, Biochemistry, 56, 525, 10.1021/acs.biochem.6b00945 · DOI · Paper page
  66. He, 2017, Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field, Sci. China Life Sci., 60, 458, 10.1007/s11427-017-9033-0 · DOI
  67. He, 2018, In vivo ovarian cancer gene therapy using CRISPR-Cas9, Hum. Gene Ther., 29, 223, 10.1089/hum.2017.209 · DOI
  68. Hoggatt, 2016, Gene therapy for “Bubble Boy” disease, Cell, 166, 263, 10.1016/j.cell.2016.06.049 · DOI
  69. Hoy, 2018, Patisiran: first global approval, Drugs, 78, 1625, 10.1007/s40265-018-0983-6 · DOI
  70. Iyer, 2017, Therapeutic angiogenesis for Peripheral Artery Disease: lessons learned in translational science, JACC Basic Transl. Sci., 2, 503, 10.1016/j.jacbts.2017.07.012 · DOI
  71. Jonsson, 2017, Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5, Virus Genes, 53, 692, 10.1007/s11262-017-1498-z · DOI
  72. June, 2018, Chimeric antigen receptor therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169 · DOI
  73. Kassner, 2018, Gene therapy in lipoprotein lipase deficiency: case report on the first patient treated with Alipogene Tiparvovec under daily practice conditions, Hum. Gene Ther., 29, 520, 10.1089/hum.2018.007 · DOI
  74. Kaufmann, 2013, Gene therapy on the move, EMBO Mol. Med., 5, 1642, 10.1002/emmm.201202287 · DOI
  75. Keam, 2018, Inotersen: first global approval, Drugs, 78, 1371, 10.1007/s40265-018-0968-5 · DOI
  76. Keeler, 2017, Gene therapy 2017: progress and future directions, Clin. Transl. Sci., 10, 242, 10.1111/cts.12466 · DOI
  77. Kim, 2017, Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: a case report, Mol. Clin. Oncol., 6, 861, 10.3892/mco.2017.1231 · DOI
  78. Kim, 2018, A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients, Hum. Gene Ther. Clin. Dev., 29, 48, 10.1089/humc.2017.249 · DOI
  79. Kitrou, 2017, Gene-based therapies in patients with critical limb ischemia, Expert. Opin. Biol. Ther., 17, 449, 10.1080/14712598.2017.1289170 · DOI
  80. Kohlhapp, 2016, Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy, Clin. Cancer Res., 22, 1048, 10.1158/1078-0432.CCR-15-2667 · DOI
  81. Kohn, 2017, How we manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID), J. Clin. Immunol., 37, 351, 10.1007/s10875-017-0373-y · DOI
  82. Korinthenberg, 2019, A new era in the management of Duchenne Muscular Dystrophy, Dev. Med. Child Neurol., 61, 292, 10.1111/dmcn.14129 · DOI
  83. Lawler, 2017, Oncolytic viruses in cancer treatment: a review, JAMA Oncol., 3, 841, 10.1001/jamaoncol.2016.2064 · DOI
  84. Ledford, 2018, Gene-silencing technology gets first drug approval after 20-year wait, Nature, 560, 291, 10.1038/d41586-018-05867-7 · DOI · Paper page
  85. Lee, 2019, Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-beta1, J. Knee Surg.
  86. Levin, 2019, Treating disease at the RNA level with oligonucleotides, N. Engl. J. Med., 380, 57, 10.1056/NEJMra1705346 · DOI · Paper page
  87. Li, 2018, Precision medicine through antisense oligonucleotide-mediated exon skipping, Trends Pharmacol. Sci., 39, 982, 10.1016/j.tips.2018.09.001 · DOI
  88. Liang, 2018, Oncorine, the world first oncolytic virus medicine and its update in China, Curr. Cancer Drug Targets, 18, 171, 10.2174/1568009618666171129221503 · DOI
  89. Lim, 2017, Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ, BMC Musculoskelet. Disord., 18, 199, 10.1186/s12891-017-1547-8 · DOI
  90. Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol., 20, 31, 10.1016/S1470-2045(18)30864-7 · DOI · Paper page
  91. Lundstrom, 2018, Viral vectors in gene therapy, Diseases, 6, E42, 10.3390/diseases6020042 · DOI · Paper page
  92. Mahadeo, 2019, Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, Nat. Rev. Clin. Oncol., 16, 45, 10.1038/s41571-018-0075-2 · DOI
  93. Marcucci, 2018, Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients, Mol. Ther., 26, 269, 10.1016/j.ymthe.2017.10.012 · DOI
  94. Mickle, 2019, The effectiveness and value of Patisiran and Inotersen for hereditary Transthyretin Amyloidosis, J. Manag. Care Spec. Pharm., 25, 10
  95. Morrison, 2018, Fresh from the biotech pipeline-2017, Nat. Biotechnol., 36, 131, 10.1038/nbt.4068 · DOI
  96. Mount, 2015, Cell-based therapy technology classifications and translational challenges, Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 370
  97. Nandakumar, 2018, Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects, J. Lipid Res., 59, 2397, 10.1194/jlr.P082834 · DOI
  98. Neelapu, 2017, Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
  99. Negre, 2016, Gene therapy of the beta-Hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene, Hum. Gene Ther., 27, 148, 10.1089/hum.2016.007 · DOI · Paper page
  100. Origa, 2017, beta-Thalassemia, Genet. Med., 19, 609, 10.1038/gim.2016.173 · DOI
  101. Ott, 2016, Talimogene Laherparepvec for the treatment of advanced melanoma, Clin. Cancer Res., 22, 3127, 10.1158/1078-0432.CCR-15-2709 · DOI
  102. Ottesen, 2017, ISS-N1 makes the first FDA-approved drug for Spinal Muscular Atrophy, Transl. Neurosci., 8, 1, 10.1515/tnsci-2017-0001 · DOI
  103. Paik, 2019, Volanesorsen: first global approval, Drugs, 79, 1349, 10.1007/s40265-019-01168-z · DOI
  104. Parekh, 2017, Complete response of advanced melanoma treated with Talimogene Laherparepvec and subsequent Sweet's-like infiltrate, JAMA Dermatol., 153, 719, 10.1001/jamadermatol.2017.0466 · DOI
  105. Parham, 2019, Mipomersen and its use in familial hypercholesterolemia, Expert. Opin. Pharmacother., 20, 127, 10.1080/14656566.2018.1550071 · DOI · Paper page
  106. Pearson, 2004, China approves first gene therapy, Nat. Biotechnol., 22, 3, 10.1038/nbt0104-3 · DOI
  107. Peng, 2005, Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers, Hum. Gene Ther., 16, 1016, 10.1089/hum.2005.16.1016 · DOI
  108. Poh, 2016, First oncolytic viral therapy for melanoma, Cancer Discov., 6, 6, 10.1158/2159-8290.CD-NB2015-158 · DOI
  109. Pol, 2016, First oncolytic virus approved for melanoma immunotherapy, Oncoimmunology, 5, 10.1080/2162402X.2015.1115641 · DOI
  110. Post, 2019, Metabolism and disposition of Volanesorsen, a 2' MOE antisense oligonucleotide, across species, Drug Metab. Dispos., 47, 1164, 10.1124/dmd.119.087395 · DOI
  111. Quintas-Cardama, 2018, CAR T-cell therapy in large B-cell lymphoma, N. Engl. J. Med., 378, 1065, 10.1056/NEJMc1800913 · DOI
  112. Raman, 2019, Talimogene Laherparepvec: review of its mechanism of action and clinical efficacy and safety, Immunotherapy, 11, 705, 10.2217/imt-2019-0033 · DOI
  113. Reeskamp, 2018, Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia, Atherosclerosis, 280, 109, 10.1016/j.atherosclerosis.2018.11.017 · DOI
  114. Riley, 2019, Delivery technologies for cancer immunotherapy, Nat. Rev. Drug Discov., 18, 175, 10.1038/s41573-018-0006-z · DOI
  115. Rinaldi, 2018, Antisense oligonucleotides: the next frontier for treatment of neurological disorders, Nat. Rev. Neurol., 14, 9, 10.1038/nrneurol.2017.148 · DOI · Paper page
  116. Roberts, 2018, Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL, Leuk. Lymphoma, 59, 1785, 10.1080/10428194.2017.1387905 · DOI
  117. Roddie, 2019, Manufacturing chimeric antigen receptor T cells: issues and challenges, Cytotherapy, 12, 327, 10.1016/j.jcyt.2018.11.009 · DOI · Paper page
  118. Rui, 2019, Non-viral delivery to enable genome editing, Trends Biotechnol., 37, 281, 10.1016/j.tibtech.2018.08.010 · DOI
  119. Russell, 2017, Efficacy and safety of Voretigene Neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial, Lancet, 390, 849, 10.1016/S0140-6736(17)31868-8 · DOI · Paper page
  120. Salter, 2018, Chimeric antigen receptor-modified T cells: CD19 and the road beyond, Blood, 131, 2621, 10.1182/blood-2018-01-785840 · DOI
  121. Sanada, 2015, Gene therapy in peripheral artery disease, Expert. Opin. Biol. Ther., 15, 381, 10.1517/14712598.2015.1007039 · DOI
  122. Schimmer, 2016, Investor outlook: rising from the Ashes; GSK's European approval of Strimvelis for ADA-SCID, Hum. Gene Ther. Clin. Dev., 27, 57, 10.1089/humc.2016.29010.ind · DOI
  123. Schubert, 2018, Chimeric antigen receptor transduced T cells: tuning up for the next generation, Int. J. Cancer, 142, 1738, 10.1002/ijc.31147 · DOI
  124. Scott, 2015, Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency, Drugs, 75, 175, 10.1007/s40265-014-0339-9 · DOI
  125. Senior, 2017, After Glybera’s withdrawal, what’s next for gene therapy?, Nat. Biotechnol., 35, 491, 10.1038/nbt0617-491 · DOI
  126. Sharma, 2018, Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas, Drugs Today (Barc), 54, 187, 10.1358/dot.2018.54.3.2776625 · DOI
  127. Sheridan, 2011, Gene therapy finds its niche, Nat. Biotechnol., 29, 121, 10.1038/nbt.1769 · DOI
  128. Shimamura, 2011, Naked plasmid DNA for gene therapy, Curr. Gene Ther., 11, 433, 10.2174/156652311798192824 · DOI
  129. Shimamura, 2014, Gene therapy for peripheral arterial disease, Expert. Opin. Biol. Ther., 14, 1175, 10.1517/14712598.2014.912272 · DOI
  130. Solomon, 2019, Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-mediated Amyloidosis: An analysis of the APOLLO study, Circulation, 139, 431, 10.1161/CIRCULATIONAHA.118.035831 · DOI · Paper page
  131. South, 2019, Strimvelis® for treating Severe Combined Immunodeficiency caused by Adenosine Deaminase Deficiency: An evidence review group perspective of a NICE highly specialised technology evaluation, Pharmacoecon Open, 3, 151, 10.1007/s41669-018-0102-3 · DOI
  132. Stein, 2017, FDA-approved oligonucleotide therapies in 2017, Mol. Ther., 25, 1069, 10.1016/j.ymthe.2017.03.023 · DOI
  133. Stirnadel-Farrant, 2018, Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID, Orphanet J. Rare Dis., 13, 49, 10.1186/s13023-018-0791-9 · DOI
  134. Suda, 2014, Beperminogene perplasmid for the treatment of critical limb ischemia, Expert. Rev. Cardiovasc. Ther., 12, 1145, 10.1586/14779072.2014.955850 · DOI
  135. Sumner, 2018, Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain, J. Clin. Invest., 128, 3219, 10.1172/JCI121658 · DOI
  136. Syed, 2016, Eteplirsen: first global approval, Drugs, 76, 1699, 10.1007/s40265-016-0657-1 · DOI
  137. Ti, 2018, Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy, Sci. China Life Sci., 61, 1320, 10.1007/s11427-018-9411-4 · DOI
  138. Vairy, 2018, CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia, Drug Des. Devel. Ther., 12, 3885, 10.2147/DDDT.S138765 · DOI
  139. Vargas, 2016, Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives, J. Transl. Med., 14, 288, 10.1186/s12967-016-1047-x · DOI
  140. Wang, 2012, Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice, Curr. Gene Ther., 12, 67, 10.2174/156652312800099599 · DOI
  141. Wang, 2018, CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research, Cancer Gene Ther., 25, 93, 10.1038/s41417-018-0016-3 · DOI
  142. Wang, 2018, Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol, Nat. Biotechnol., 36, 717, 10.1038/nbt.4182 · DOI
  143. Wang, 2019, Adeno-associated virus vector as a platform for gene therapy delivery, Nat. Rev. Drug Discov., 18, 358, 10.1038/s41573-019-0012-9 · DOI · Paper page
  144. Wang, 2019, Clinical translation of gene medicine, J. Gene Med., 21, e3108, 10.1002/jgm.3108 · DOI
  145. Watanabe, 2018, Oncolytic virotherapy by HSV, Adv. Exp. Med. Biol., 1045, 63, 10.1007/978-981-10-7230-7_4 · DOI
  146. Wei, 2017, Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses, Cell. Physiol. Biochem., 41, 2383, 10.1159/000475909 · DOI
  147. Weinmann, 2017, Next-generation AAV vectors for clinical use: an ever-accelerating race, Virus Genes, 53, 707, 10.1007/s11262-017-1502-7 · DOI
  148. Willyard, 2012, Limb-saving medicines sought to prevent amputations, Nat. Med., 18, 328, 10.1038/nm0312-328 · DOI
  149. Wilson, 2005, Gendicine: the first commercial gene therapy product, Hum. Gene Ther., 16, 1014, 10.1089/hum.2005.16.1014 · DOI
  150. Wilson, 2009, Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency, Mol. Genet. Metab., 96, 151, 10.1016/j.ymgme.2008.12.016 · DOI · Paper page
  151. Yla-Herttuala, 2012, Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union, Mol. Ther., 20, 1831, 10.1038/mt.2012.194 · DOI
  152. Zhang, 2017, Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials, Signal Transduct. Target. Ther., 2, 17054, 10.1038/sigtrans.2017.54 · DOI
  153. Zhang, 2018, The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 Years in the clinic, Hum. Gene Ther., 29, 160, 10.1089/hum.2017.218 · DOI
  154. Zhao, 2018, Universal CARs, universal T cells, and universal CAR T cells, J. Hematol. Oncol., 11, 132, 10.1186/s13045-018-0677-2 · DOI
  155. Zheng, 2018, Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts, Drug Discov. Today, 23, 1175, 10.1016/j.drudis.2018.02.012 · DOI
  156. Zhou, 2018, Current advances in small activating RNAs for gene therapy: principles, applications and challenges, Curr. Gene Ther., 18, 134, 10.2174/1566523218666180619155018 · DOI

Cited by

Sorted by citations

See all 310

Metadata

Authors
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q.
Venue
Biotechnology Advances
Publisher
Elsevier BV
Published
2020-05
Volume
40
Pages
107502
ISSN
0734-9750
DOI
10.1016/j.biotechadv.2019.107502
Cited by
310
References
22
Language
en
Licence
Funders
  • West China Hospital, Sichuan University (ZYJC18028)
  • National High-tech Research and Development Program (2014AA020708, 2015AA020309)
  • National Science Fund for Distinguished Young Scholars (31525009)
  • Sichuan Province Science and Technology Support Program (2019YFG0266, 2018GZ0311)
  • Sichuan University
  • China Postdoctoral Science Foundation (2015M570791)
  • National Natural Science Foundation of China (81602699)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review